LEXICON PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
LXRX$1.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(200,403) | $(177,119) | $(101,944) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 534 | 554 | 427 |
| Stock-based compensation | 13,499 | 14,340 | 11,520 |
| Amortization of debt-related costs | 1,845 | 1,774 | 741 |
| Loss on disposal of property and equipment | — | — | 3 |
| Accretion of marketable securities purchased at a discount | (9,305) | (5,617) | — |
| Other non-cash adjustments | 812 | 1,512 | — |
| Changes in operating assets and liabilities: | |||
| Increase in accounts receivable | (2,463) | (982) | (14) |
| Decrease (increase) in inventories | 150 | (381) | — |
| Decrease (increase) in prepaid expenses and other current assets | 598 | (2,899) | (316) |
| Decrease in other long-term assets | 1,152 | 467 | 656 |
| Increase in accounts payable and other liabilities | 14,801 | 6,454 | 76 |
| Net cash used in operating activities | (178,780) | (161,897) | (88,851) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (1,031) | (470) | (1,326) |
| Purchases of investments | (328,747) | (223,343) | (133,949) |
| Maturities of investments | 314,400 | 173,870 | 64,197 |
| Net cash used in investing activities | (15,378) | (49,943) | (71,078) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock, net of fees | — | 138,823 | 94,205 |
| Proceeds from issuance of common stock for equity incentive plans | 64 | — | — |
| Proceeds from issuance of preferred stock, net of fees | 241,322 | — | — |
| Repurchase of common stock | (1,730) | (824) | (864) |
| Proceeds from debt borrowings, net of fees | — | 49,961 | 48,868 |
| Other debt financing fees | (1,307) | — | — |
| Net cash provided by financing activities | 238,349 | 187,960 | 142,209 |
| Net increase (decrease) in cash and cash equivalents | 44,191 | (23,880) | (17,720) |
| Cash and cash equivalents at beginning of year | 22,465 | 46,345 | 64,065 |
| Cash and cash equivalents at end of year | $66,656 | $22,465 | $46,345 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $12,919 | $10,057 | $2,289 |
| Supplemental disclosure of noncash investing and financing activities: | |||
| Right-of-use assets obtained in exchange for operating lease liability | $— | $— | $5,206 |
| Issuance of equity-classified warrants | $— | $307 | $1,030 |
| Issuance of treasury stock | $— | $— | $6,321 |
| Accrual of deferred financing costs | $— | $250 | $— |
| Conversion of preferred stock to common stock | $115 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.